BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27917904)

  • 1. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer.
    Cao Y; Zhang H; Liu H; Lin C; Li R; Wu S; He H; Li H; Xu J
    Sci Rep; 2016 Dec; 6():38364. PubMed ID: 27917904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients.
    Cao Y; Liu H; Zhang H; Lin C; Li R; Wu S; Li H; He H; Zhang W; Xu J
    Oncotarget; 2017 Mar; 8(12):20328-20339. PubMed ID: 27780937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
    Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
    Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W; Zeng X; Li N; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
    Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
    Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topographic lymph node staging system shows prognostic superiority compared to the 8th edition of AJCC TNM in gastric cancer. A western monocentric experience.
    Lauricella S; Caricato M; Mascianà G; Carannante F; Carnazza M; Bonaccorso A; Angeletti S; Ciccozzi M; Coppola R; Capolupo GT
    Surg Oncol; 2020 Sep; 34():223-233. PubMed ID: 32869748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the staging of regional lymph nodes using the sixth and seventh editions of the tumor-node-metastasis (TNM) classification system for the evaluation of overall survival in gastric cancer patients: findings of a case-control analysis involving a single institution in China.
    Deng J; Zhang R; Pan Y; Wang B; Wu L; Jiao X; Bao T; Hao X; Liang H
    Surgery; 2014 Jul; 156(1):64-74. PubMed ID: 24929759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term Outcomes of Laparoscopy-assisted Gastrectomy for T4a Advanced Gastric Cancer: A Single-center Retrospective Study.
    Zhang L; Zang L; Sun J; Dong F; Feng B; Lu AG; Wang ML; Zheng MH; Ma JJ; Hu WG
    Surg Laparosc Endosc Percutan Tech; 2019 Dec; 29(6):476-482. PubMed ID: 31259865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
    Cao Y; Liu H; Li H; Lin C; Li R; Wu S; Zhang H; He H; Zhang W; Xu J
    JAMA Surg; 2017 Nov; 152(11):e173120. PubMed ID: 28903131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes.
    Alatengbaolide ; Lin D; Li Y; Xu H; Chen J; Wang B; Liu C; Lu P
    Am J Clin Oncol; 2013 Aug; 36(4):325-30. PubMed ID: 22547011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].
    Li B; Sun L; Wang X; Deng J; Ding X; Wang X; Ke B; Zhang L; Zhang R; Liang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):207-212. PubMed ID: 28226357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
    Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
    Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery.
    Wu S; Liu H; Zhang H; Lin C; Li R; Cao Y; He H; Li H; Shen Z; Qin J; Xu J
    Tumour Biol; 2016 Sep; 37(9):12635-12642. PubMed ID: 27444274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy.
    Ma T; Wu ZJ; Xu H; Wu CH; Xu J; Peng WR; Fan LL; Sun GP
    BMC Cancer; 2019 Aug; 19(1):852. PubMed ID: 31462229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and external validation of a nomogram for predicting the conditional probability of survival after D2 lymphadenectomy for gastric cancer: A multicentre study.
    Chen QY; Zhong Q; Wang W; Desiderio J; Liu ZY; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Li P; Zheng CH; Zhou ZW; Parisi A; Huang CM
    Eur J Surg Oncol; 2019 Oct; 45(10):1934-1942. PubMed ID: 31027946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis.
    Zheng XH; Zhang W; Yang L; Du CX; Li N; Xing GS; Tian YT; Xie YB
    World J Gastroenterol; 2019 May; 25(19):2338-2353. PubMed ID: 31148905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of long-term results of radical gastrectomy combining splenectomy for gastric cancer].
    Han FH; Zhan WH; Li YM; He YL; Peng JS; Ma JP; Wang Z; Chen ZX; Zheng ZQ; Wang JP; Huang YH; Dong WG
    Zhonghua Wai Ke Za Zhi; 2005 Sep; 43(17):1114-7. PubMed ID: 16194307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.